Lisata Therapeutics (NASDAQ:LSTA) Issues Earnings Results

Lisata Therapeutics (NASDAQ:LSTA) announced its earnings results on Monday. The company reported ($0.50) earnings per share for the quarter, FiscalAI reports.

Lisata Therapeutics Trading Up 3.5%

LSTA opened at $3.26 on Tuesday. The stock has a 50-day moving average price of $4.32 and a 200-day moving average price of $3.34. Lisata Therapeutics has a 12-month low of $1.81 and a 12-month high of $5.07. The stock has a market capitalization of $29.70 million, a P/E ratio of -1.71 and a beta of 0.81.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. lowered Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $15.00.

Hedge Funds Weigh In On Lisata Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of LSTA. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics in the 2nd quarter worth about $32,000. Ground Swell Capital LLC purchased a new position in shares of Lisata Therapeutics in the 3rd quarter worth about $62,000. CIBC Bancorp USA Inc. purchased a new position in shares of Lisata Therapeutics in the 3rd quarter worth about $37,000. Renaissance Technologies LLC boosted its holdings in shares of Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares in the last quarter. Finally, Deltec Asset Management LLC purchased a new position in shares of Lisata Therapeutics in the 1st quarter worth about $451,000. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.